UA87958C2 - Мутанты ifnar2, их получение и применение - Google Patents

Мутанты ifnar2, их получение и применение

Info

Publication number
UA87958C2
UA87958C2 UA20040605186A UA20040605186A UA87958C2 UA 87958 C2 UA87958 C2 UA 87958C2 UA 20040605186 A UA20040605186 A UA 20040605186A UA 20040605186 A UA20040605186 A UA 20040605186A UA 87958 C2 UA87958 C2 UA 87958C2
Authority
UA
Ukraine
Prior art keywords
beta
hepatitis
chronic
mutant
ifn
Prior art date
Application number
UA20040605186A
Other languages
English (en)
Ukrainian (uk)
Inventor
Гідеон Шрайбер
Original Assignee
Йєда Рісьорч Енд Девелопмент Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йєда Рісьорч Енд Девелопмент Ко. Лтд. filed Critical Йєда Рісьорч Енд Девелопмент Ко. Лтд.
Publication of UA87958C2 publication Critical patent/UA87958C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Abstract

Изобретение относится к мутантным полипептидам бета-цепи рецептора IFN типа І (мутант IFNAR2) с повышенным родством к интерферону-бета, сравнительно с белком дикого типа, для продолжения эффекта IFN-бета in vivo, и применение указанных мутантных полипептидов для изготовления лекарственного средства для лечения рассеянного склероза, ревматоидного артрита, трудной псевдопаралитической миастении, диабета, обычной волчанки и неспецифичного язвенного колита, хронического гранулематоза, остроконечной кондиломы, юношеского ларингопапиломатоза, гепатита А или хронической инфекции вирусами гепатитов В и С, волосатоклеточного лейкоза, саркомы Капоши, множественной миеломы, хронического миелолейкоза, неходжкинской лимфомы или меланомы.
UA20040605186A 2001-12-31 2002-12-31 Мутанты ifnar2, их получение и применение UA87958C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14741401A IL147414A0 (en) 2001-12-31 2001-12-31 Ifnar2 mutants, their production and use

Publications (1)

Publication Number Publication Date
UA87958C2 true UA87958C2 (ru) 2009-09-10

Family

ID=11075916

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040605186A UA87958C2 (ru) 2001-12-31 2002-12-31 Мутанты ifnar2, их получение и применение

Country Status (15)

Country Link
US (2) US7749735B2 (ru)
EP (2) EP1461358A1 (ru)
JP (2) JP2005527195A (ru)
KR (1) KR100891918B1 (ru)
CN (1) CN100506845C (ru)
BR (1) BR0215414A (ru)
CA (1) CA2470245C (ru)
EA (1) EA009604B1 (ru)
IL (2) IL147414A0 (ru)
MX (1) MXPA04006383A (ru)
NO (1) NO333821B1 (ru)
NZ (1) NZ533539A (ru)
UA (1) UA87958C2 (ru)
WO (1) WO2003059950A1 (ru)
ZA (1) ZA200404731B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
CN103952413B (zh) * 2014-05-14 2016-08-17 广东省农业科学院动物卫生研究所 靶向ifnar2基因的rna干扰表达载体构建及应用
CN104762325B (zh) * 2015-03-30 2018-04-17 山东省农业科学院家禽研究所 一种沉默df‑1细胞系中ifnar2基因的方法
CN105396123A (zh) * 2015-11-20 2016-03-16 深圳市南山区人民医院 ovR2E蛋白在HBV感染治疗中疗效的应用
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
EP0536520B1 (en) 1985-10-14 1999-03-03 Yeda Research And Development Co. Ltd. Use of Human Interferon-Beta 2A for the preparation of medicaments
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IL107378A (en) 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
BR9707589A (pt) * 1996-02-20 2000-01-04 Applied Research Systems Proteìna hìbrida, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica e processos para produzir proteìna hìbrida e para induzir maturação folicular.
WO1999032141A1 (en) * 1997-12-19 1999-07-01 Applied Research Systems Ars Holding N.V. Ifnar2/ifn complex
IL126562A0 (en) 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation

Also Published As

Publication number Publication date
JP2005527195A (ja) 2005-09-15
WO2003059950A1 (en) 2003-07-24
CA2470245A1 (en) 2003-07-24
MXPA04006383A (es) 2004-10-04
US7749735B2 (en) 2010-07-06
EA200400894A1 (ru) 2004-12-30
EP2174955A1 (en) 2010-04-14
CN100506845C (zh) 2009-07-01
IL162507A (en) 2011-01-31
NO333821B1 (no) 2013-09-23
EP1461358A1 (en) 2004-09-29
JP2009165483A (ja) 2009-07-30
KR20040086255A (ko) 2004-10-08
KR100891918B1 (ko) 2009-04-08
HK1072948A1 (zh) 2005-09-16
NZ533539A (en) 2008-05-30
EP2174955B1 (en) 2014-04-16
ZA200404731B (en) 2005-08-31
US20050164185A1 (en) 2005-07-28
CN1622957A (zh) 2005-06-01
NO20042768L (no) 2004-09-22
BR0215414A (pt) 2004-12-14
EA009604B1 (ru) 2008-02-28
CA2470245C (en) 2012-03-27
IL147414A0 (en) 2002-08-14
US20100239530A1 (en) 2010-09-23
AU2002366976A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
Luxon et al. Pegylated interferons for the treatment of chronic hepatitis C infection
Bekisz et al. Mini ReviewHuman interferons alpha, beta and omega
Li et al. Interferon-λs: the modulators of antivirus, antitumor, and immune responses
PT1085904E (pt) Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
NZ707821A (en) Ergonomic and adjustable respiratory mask assembly
FI935113A0 (fi) Oligonukleotidanaloger med modifierad stomme
MY127670A (en) Pegylated interferon alfa-ccr5 antagonists combination hiv therapy
NZ329970A (en) Use of IFN-beta mutein derivatives for treating viral infections
NZ504771A (en) IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)
Walter et al. Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon
MXPA03010336A (es) Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes.
Grace et al. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway
Sulkowski et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
Schlaepfer et al. Dose-dependent differences in HIV inhibition by different interferon alpha subtypes while having overall similar biologic effects
CA2427850A1 (en) Interferons, uses and compositions related thereto
Hu et al. Human IFN-α protein engineering: The amino acid residues at positions 86 and 90 are important for antiproliferative activity
Jacobs et al. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor
HUP0300354A2 (hu) HIV immunadjuváns terápia
Wijesundara et al. Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design
Koyama et al. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication
EP0724587A4 (en) NUCLEOSIDES AND NUCLEOTIDES WITH EXTENDED CYCLES
Yano et al. Growth inhibitory effects of interferon‐α subtypes vary according to human liver cancer cell lines
US7695710B2 (en) Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
MXPA04006383A (es) Polipeptidos mutantes de la cadena beta del receptor de interferon tipo i, su produccion y uso.
Herz et al. Human interferon-α-and-γ-mediated inhibition of retrovirus production in the absence of an inhibitory effect on vesicular stomatitis virus and encephalomyocarditis virus replication in RD-114 cells